Baker McKenzie advises shareholders of Biopharma on the sale of pharmaceutical business to Stada AG

Kyiv, Ukraine — 30 January 2020. The Kyiv office of Baker McKenzie advised the shareholders of Biopharma, a leading Ukrainian manufacturer of pharmaceuticals and healthcare products, on the carve-out of its non-plasma business and its further sale to Stada AG, a global manufacturer of pharmaceuticals and consumer healthcare products.

This transaction was completed in December 2019 and it represents one of the largest investments by a multinational strategic investor in pharmaceutical sector in Ukraine.

The Baker McKenzie team was co-led by Kyiv office partners Viacheslav Yakymchuk, head of the Corporate M&A practice group, and Olha Demianiuk, head of the Healthcare & Life Sciences industry group, with key input from associates Andrii Finogin, Olha Sviatenka and Khrystyna Penyk in Kyiv, and London-based senior corporate associate Robert Gray. The team also included antitrust and competition partner Oksana Simonova and senior associate Olha Mikheieva. 

Baker McKenzie team advised on the carve of the pharmaceutical business of Biopharma from its plasma business, drafted and negotiated transaction documents, assisted with obtaining approvals from the Antimonopoly Committee of Ukraine, and more.

Commenting on the transaction, Viacheslav Yakymchuk noted: "We are privileged to have advised our client on the successful sale of the pharmaceutical business. Our team supported the shareholders of Biopharma with their investments in and expansion of the Biopharma's pharmaceutical business since 2012. This project highlights our strategic focus on complex transactions which require sophisticated industry expertise."

Commenting on the transaction, Olha Demianiuk noted: "We are extremely proud that we have advised our long-standing client Biopharma on this milestone transaction - its exit from the non-plasma business. The acquisition demonstrates high recognition of Biopharma's pharmaceutical business by a reputable strategic investor. This is yet another sign for investors of the immense opportunities offered by the pharmaceutical industry in Ukraine."

Konstantin Efimenko, Biopharma’s Managing Partner noted: "We are proud to have built a strong business, that attracted a major global investor. This was a truly unique and extremely complex transaction, which was successfully closed with the help of our legal consultants. We are happy to have closed this deal and thank Baker McKenzi'e team for seamless work and committed efforts."

For more information, please contact: